About HYD
HYD LLC was established in 1992 for the development and worlwide marketing of drugs and consumer products, that utilize the proprietary procedure, deuterium depletion. Since 1993, the company has been pioneering in research and drug development related to deuterium depletion, and was worldwide the first to investigate the biological role and physiological importance of naturally occurring deuterium. The company’s mission is to develop and register novel pharmaceutical and consumers products primarily for the treatment and prevention of tumorous diseases, and to open up new ways of application of the method in further ranges of indication. The first anticancer drug based on deuterium depletion ( Vetera-DDW-25 ® A.U.V. ) was registered by HYD LLC for veterinary use in 1999. Vetera-DDW-25 has been effective in combination with surgery or as a single treatment. Mammary tumors in dogs and cats showed a response rate higher than 70%; more than 50% of the animals achieved complete recovery. In 2012, Primus Capital closed a USD 2 Million investment in HYD Pharma Inc. The investment is being used for validation of research results, and for implementation of a new human phase II clinical test.
- Industry : Pharma
